Pharmafocus.com

Latest Features ( October )
	A postcard from ... Slovakia We take a look at how this young country is managing healthcare and controlling costs(more)
	The Pharmafocus Interview: Jan Lundberg AstraZeneca's global head of drug discovery talks about new compounds, learning from mistakes and the real heroes behind life-saving drugs.(more)
	Emerging confidence Evidence-based medicine is an evolving practice, even in the developed world, but proving value is getting tougher in emerging markets too, says Ben Shankland(more)

Back to News Index

AstraZeneca fights generic Nexium bid
Friday , November 25, 2005

AstraZeneca has filed a lawsuit in the US courts to block the launch of a generic version of Nexium.

The ulcer treatment is AstraZeneca's biggest selling brand, and is expected to earn the company around $4.5 billion this year - revenue the company is determined to protect.

Indian generics company Ranbaxy wants to launch its own version of the drug in the US, but AstraZeneca says it infringes six separate patents, which could provide it with market exclusivity up to 2019.

AstraZeneca recently filed a lawsuit to tackle a separate generic challenge to another of its leading brands, schizophrenia blockbuster Seroquel.

Related articles:

Oxford and GSK to collaborate on cancer research in India

Friday , November 18, 2005

pharmafocus@wiley.co.uk